Stocktoria

Cabaletta Bio, Inc. CABA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-25

Cabaletta Bio, Inc. statistics & valuation

Market cap$495.7M
P / B4.4×
Return on equity-149.8%
Return on capital-149.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20182019202020212022202320242025
Operating margin (%)
20182019202020212022202320242025
Return on equity (%)
-12.20% -30.40% -39.20% -50.70% -28.70% -76.10% -149.80% 20182019202020212022202320242025
Shares outstanding
3.8M 24.0M 24.1M 28.9M 29.4M 47.8M 50.7M 100.5M 20182019202020212022202320242025
Net debt ($)
20182019202020212022202320242025
Share buybacks ($)
20182019202020212022202320242025
Return on assets (%)
-35.70% -12.00% -29.10% -36.60% -45.30% -26.70% -62.60% -101.70% 20182019202020212022202320242025
Free cash flow margin (%)
20182019202020212022202320242025
Debt / equity (×)
20182019202020212022202320242025
EPS ($)
-$1.80 -$1.81 -$1.65 -$2.34 -$2.10 20182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Return on assets-101.7%-62.6%-26.7%-45.3%-36.6%-29.1%-12.0%-35.7%
Return on equity-149.8%-76.1%-28.7%-50.7%-39.2%-30.4%-12.2%114.1%
Current ratio2.776.1515.2911.4714.8621.9244.6636.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.